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Evidence suggests that depression is a risk factor for dementia; however, the relationship between the two conditions is not fully understood.
A novel gene (TOMM40) has been consistently associated with Alzheimer’s disease (AD), but has received no attention in depression. We
conducted a three-level cross-sectional study to investigate the association of the TOMM40 rs2075650 SNP with depression. We recruited
a community sample of 1220 participants (571 controls, 649 lifetime depression) to complete a psychiatric background questionnaire, the
Brief Symptom Inventory, and Big Five Inventory at Level-1, 243 (102 controls, 97 remitted, 44 currently depressed) to complete a face-to-
face clinical interview and neuropsychological testing at Level-2 and 58 (33 controls, 25 remitted) to complete an emotional face-processing
task during fMRI at Level-3. Our results indicated that the TOMM40 rs2075650 G allele was a significant risk factor for lifetime depression
(p¼ 0.00006) and, in depressed subjects, was a significant predictor of low extraversion (p¼ 0.009). Currently depressed risk allele carriers
showed subtle executive dysfunction (p¼ 0.004) and decreased positive memory bias (p¼ 0.021) together with reduced activity in the
posterior (p(FWE)¼ 0.045) and anterior (p(FWE)¼ 0.041) cingulate during sad face emotion processing. Our results suggest that TOMM40
rs2075650 may be a risk factor for the development of depression characterized by reduced extraversion, impaired executive function, and
decreased positive emotional recall, and reduced top-down cortical control during sad emotion processing.
Neuropsychopharmacology (2014) 39, 1743–1753; doi:10.1038/npp.2014.22; published online 19 February 2014
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INTRODUCTION
There is a near two-fold increased risk of developing
dementia, particularly Alzheimer’s disease (AD), after a
diagnosis of depression (Green et al, 2003; Jorm, 2001;
Ownby et al, 2006; Saczynski et al, 2010). This risk may
be partially explained by depression forming a dementia
prodrome, given the higher risk of dementia in late-life
depression compared with earlier onset depression (Barnes
et al, 2012). However, this cannot explain the greater risk of
developing dementia in those who only suffer from depres-
sion earlier in their lives (Green et al, 2003), suggesting
common biology linking the conditions. If true, then genetic
factors associated with an increased risk of dementia may also
contribute to an increased risk of depression.
Genetic susceptibility to developing AD is well recog-
nized. Both the apolipoprotein E (APOE) gene and the
TOMM40-APOE locus, tagged by rs2075650 in the translo-
case of outer mitochondrial membrane 40 (TOMM40) gene
(see Supplementary Information), have been implicated
(Hong et al, 2010; Li et al, 2008; Schiepers et al, 2011).
Investigations of depression have also indicated that the
APOE e4 risk allele influences both the onset and risk for
late-life depression (Butters et al, 2003; Yen et al, 2007) and
has been associated with gray matter reductions (Cherbuin
et al, 2007), reduced white matter integrity (Heise et al,
2011) and cognitive impairment (Greenwood et al, 2000) in
healthy adults, further suggesting that genetic mechanisms
associated with dementia may contribute to the develop-
ment of mood disorder.
In comparison to APOE, the independent role of
TOMM40 in AD and depression has been little studied.
In large genome-wide association studies of AD, TOMM40
rs2075650 (intron 2, chromosome 19q13.32) has been one
of the most significantly associated single-nucleotide
polymorphisms (SNPs) (Harold et al, 2009; Naj et al,
2010; Seshadri et al, 2010). TOMM40 encodes a protein
on the outer mitochondrial membrane essential for cell
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viability, thus variation in this gene could lead to
mitochondrial dysfunction (Ferencz et al, 2012; Pfanner
et al, 1997), of which dementia and depression are
symptoms (Anglin et al, 2012; Fattal et al, 2007). TOMM40
rs2075650 is in linkage disequilibrium (LD) with the APOE
e4 rs429358 SNP (Harold et al, 2009; Potkin et al, 2009).
However, evidence of an extended TOMM40-APOE haplo-
type that influences the regional effects and onset age of AD
(Bekris et al, 2010; Roses, 2010) suggests that TOMM40 may
have APOE-independent effects (Carrasquillo and Morgan,
2012). Even in relation to AD the risk associated with
TOMM40 cannot be fully explained by LD, and it has been
suggested that other SNPs must contribute (Bekris et al,
2012). Despite TOMM40 rs2075650 being a good candidate
for major depressive disorder (MDD), its possible effect on
depression-related phenotypes has not yet been investigated.
Pathophysiological similarities between MDD and AD
provide candidate intermediate phenotypes that may
identify shared genetic factors. Alterations in premorbid
measures of personality factors have been demonstrated in
both depression (Kendler et al, 2006a) and AD (Robins
Wahlin and Byrne, 2011). Cognitive deficits are well-
reported features of both MDD (Millan et al, 2012) and
AD (Christensen et al, 1997) that share similar structural
and functional brain abnormalities in regions such as
hippocampus (Arnone et al, 2012a; Potkin et al, 2009; Shen
et al, 2010), amygdala (Drevets et al, 2008; Shen et al, 2010),
cingulate (Johnson et al, 2011; Pizzagalli, 2011; Ries et al,
2009), and dorsolateral prefrontal cortex (Morbelli et al,
2012; Pizzagalli, 2011). TOMM40 itself has also been
associated with hippocampal atrophy (Potkin et al, 2009;
Shen et al, 2010) in AD patients and reduced gray matter
in the cingulate of healthy controls (Johnson et al, 2011).
Variations in TOMM40 may therefore contribute to a
biological vulnerability independent of APOE that under-
pins aspects of both AD and MDD.
In this study, we took an exploratory multiple-level
hypothesis-testing approach, using intermediate pheno-
types, to investigate the role of the minor (G) allele of
TOMM40 rs2075650 in vulnerability to MDD. We tested
the association between rs2075650, lifetime depression, and
depressive symptoms in a large cohort and assessed
whether personality traits are overexpressed in minor allele
carriers. We then assessed whether the minor allele was
associated with poorer cognitive function than the AA
genotype using tests of memory, executive control, and
affective bias. Finally, we investigated the effects of this SNP
on brain function using a functional magnetic resonance
imaging (fMRI) face emotion processing task as a putative
neurobiological marker for depression (Juhasz et al, 2011),
hypothesizing that risk allele carriers would show similar
patterns of brain activations to those seen in currently
depressed individuals.
MATERIALS AND METHODS
Participants
Participants aged 18–60 years, predominantly from Greater
Manchester, were recruited primarily through NHS general
practices and the study website. Detailed description of the
recruitment methodology has been published previously
(Juhasz et al, 2009; Juhasz et al, 2011). In summary, self-
reported diagnostic and demographic data were collected
from the Level-1 community sample, where a final cohort of
1220 participants was selected for the current investigation.
All included participants were of Caucasian origin, provided
DNA, and successfully genotyped for TOMM40 rs2075650,
with no self-reported history of manic or hypomanic
episodes, psychotic symptoms, or obsessive-compulsive
disorder. From this initial pool, 129 participants completed
a face-to-face clinical interview and an additional neurop-
sychological testing session. This sample was further
enhanced with 114 participants recruited through advertise-
ments, providing a total of 243 participants in the Level-2
cohort. Finally, a subset of 58 participants from Level-2
completed an fMRI scan at Level-3. Further details of the
recruitment can be found in the Supplementary Information.
All participants provided written informed consent, and the
study was approved by the local ethics committees and
carried out in accordance with the Declaration of Helsinki.
Level-1 Assessment
The Background Questionnaire included in the Level-1
questionnaire booklet has been detailed previously (Juhasz
et al, 2009; Juhasz et al, 2011). Briefly, this questionnaire
included items designed to probe personal psychiatric
history, allowing for the coding of participants as either
healthy controls or those who reported suffering from
depression during their lifetime (see Supplementary
Information). Self-reported lifetime depression was used
to analyze genetic associations. The Brief Symptom
Inventory was used to assess current psychiatric symptoms.
Personality was measured using the Big Five Inventory
(BFI-44) (John et al, 1991), a 44-item instrument that
assesses traits of neuroticism, extraversion, openness to
experience, agreeableness, and conscientiousness.
Level-2 Assessment
In addition to the information provided in the Level-1
background questionnaire, clinical diagnoses were
established by trained researchers using the Structured
Clinical Interview for DSM-IV (SCID-I/NP; First et al,
2002). Participants were grouped into controls (no lifetime
psychiatric disorders), remitted depressed (past MDD
currently in full remission), and currently depressed
(current MDD or MDD in partial remission). Current
depressive symptoms were measured using the Montgom-
ery–A˚sberg Depression Rating Scale (MADRS; Montgomery
and A˚sberg, 1979). Data from the diagnosed participants
were used to validate the Level-1 questionnaire (see Juhasz
et al, 2011).
The neuropsychological assessment included tasks known
to be sensitive to depression (Elliott et al, 2011; Millan et al,
2012). The n-back task (Owen et al, 2005) was used as a
measure of working memory, as previous work has
demonstrated that this paradigm is sensitive to deficits in
both AD and depression (Harvey et al, 2005; Waltz et al,
2004). The CANTAB Stockings of Cambridge (SoC; http://
www.camcog.com/) task was used as an index of planning
and executive function, as previous studies using the SoC
have demonstrated executive deficits in depression (Beats
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et al, 1996; Elliott et al, 1996). Finally, an emotional word
memory task, based on the work of Harmer et al (2009), was
used as a measure sensitive to changes in affective bias and
memory performance in depression. See Supplementary
Information for details.
Level-3 Assessment
To assess whether changes in affective processing were
associated with carrying the rs2075650 risk allele as distinct
from current depressive mood, only healthy controls and
remitted patients (with a MADRS score ofp10) underwent
fMRI scanning.
fMRI Image Acquisition
Participants were scanned using a 1.5 T Philips Intera while
performing an emotional face-processing paradigm (Thomas
et al, 2011). During this task, participants were asked to
identify the gender of faces selected from the Ekman and
Friesen (1976) stimuli displaying either a neutral expression,
happiness, sadness, or fear (see Supplementary Information
for details). Data were acquired using a T2*-weighted
gradient echo-planar sequence with a repetition time
(TR) of 2.1 s and an echo time (TE) of 40 ms. Each
volume consisted of 29 contiguous axial slices (thickness
4.5 mm, inter-slice gap 0.5 mm). Voxel size was 3.5 3.5 5
mm3. A T1-weighted structural scan was acquired for
preprocessing.
Genotyping
The TOMM40 rs2075650 SNP was genotyped using the
Sequenom MassARRAY technology (Sequenom, San Diego).
See Supplementary Information for information on geno-
typing.
Statistical Analysis
Level-1 genetic association analysis. PLINK v1.07 (http://
pngu.mgh.harvard.edu/purcell/plink/) was used for testing
Hardy–Weinberg equilibrium and associations of different
genetic models (dominant (DOM), recessive (REC) and
additive (ADD)), using linear and logistic regression
between TOMM40 rs2075650 and phenotypes of interest
(for power calculations, see Supplementary Information).
Age and sex were covariates in all the analyses. Main effects
of genotype were investigated using lifetime depression
and current depression. Personality factors as possible
intermediate phenotypes were tested by the main effects of
genotype and by the genotype depression status (current
or lifetime) interaction. The positive false discovery rate
(pFDR; q-value: http://genomics.princeton.edu/storeylab/
qvalue/) was applied simultaneously across all models to
maintain an a of 0.05 (Storey and Tibshirani, 2003).
Level-2 neuropsychological behavioral data analysis.
The neuropsychological results were analyzed using SPSS
19 (http://www.ibm.com/software/analytics/spss/). Data
were appropriately transformed to satisfy parametric
assumptions. The 0-back condition of n-back was removed
as performance was error-free. Age, sex, and current
depression medication (as a binary indicator variable)
were treated as covariates in all the models. To test the
intermediate phenotype role of cognitive and affective
domains, a single MANCOVA was performed for each
outcome of each task, with the outcome vector comprising
a linear combination of the task conditions. The multivariate
main effects and interactions (using Pillai’s Trace) were used
to infer effects of diagnosis, genotype, and diagnosis
genotype interactions. Significant diagnosis genotype inter-
actions were followed-up by assessing each of the individual
task conditions as univariate between-subject ANOVA models
in order to explore the direction of any interaction effects.
Post-hoc testing was conducted on the univariate models
using pairwise contrasts across the interaction term with the
Sˇida´k multiple-comparison correction. Due to the multiplicity
inherent in testing multiple non-independent MANCOVA
models, the same pFDR correction used in Level-1 was
applied simultaneously across main effects and interactions.
See Supplementary Information for details.
Level-3 imaging data analysis. The Level-3 imaging
data were analyzed using Statistical Parametric Mapping
(SPM8; http://www.fil.ion.ucl.ac.uk/spm/). Image prepro-
cessing has been detailed previously (Thomas et al, 2011).
At the first level, b^ contrast maps of activation change were
created by subtracting the neutral condition from each
facial emotion of interest (happy, sad, and fear). For the
second level analysis, each of the individual b^ contrasts
created in the first level were used as raw Y vector values in
the linear model. The model was a standard factorial cell-
means design constructed from genotype and diagnosis.
Age, sex, and MADRS scores were entered as covariates,
with the continuous measures mean-centered. Our initial
analysis was also restricted to the sad-neutral contrast as the
most reliable biomarker for MDD (Arnone et al, 2012b).
Exploratory post-hoc analyses for happy-neutral and fear-
neutral were also conducted.
Based on a priori hypotheses, region of interest (ROI)
analyses of the areas common to MDD and AD discussed
earlier (Arnone et al, 2012a; Drevets et al, 2008; Johnson
et al, 2011; Macqueen and Frodl, 2011; Morbelli et al, 2012;
Pizzagalli, 2011; Potkin et al, 2009; Ries et al, 2009; Shen
et al, 2010) were conducted using the PickAtlas toolbox
(http://fmri.wfubmc.edu/software/PickAtlas). All regions
were included bilaterally in a single mask consisting of
Brodmann areas (BA) 46, posterior cingulate cortex (PCC),
anterior cingulate cortex (ACC), hippocampus, and amyg-
dala. All results are reported at a ROI-corrected a of
p(FWE)p0.05 using the MNI standard.
RESULTS
Demographic information for all three levels is presented in
Table 1. Participants were similar in age and sex across all
groups, with more females than males as expected. The
distribution of the AA genotype and the G allele carriers
(GA/GG) within each diagnostic group is also presented.
TOMM40 rs2075650 SNP was in HWE in all levels and in all
subgroups.
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Level-1
Lifetime depression was significantly more frequent in G
allele carriers in both additive and dominant models
(Table 2). No relationship was shown for the recessive
model. All further testing was conducted using a dominant
model where GA and GG participants were collapsed into a
single group due to the rarity (2% of the sample) of the GG
genotype. For the remainder of the paper, our use of the G
allele should be read as synonymous with GA and GG
combined. G allele carriers did not have significantly greater
current depression scores than non-carriers. Scores on the
BFI-44-derived personality traits were not significantly
affected by genotype. However, in those who suffered from
current or past depression the possession of the risk G allele
enhanced the low extraversion trait (significant genotype
lifetime depression/current depression scores interaction).
There were no statistically significant interactions affecting
other personality traits. A post-hoc analysis demonstrated
that the association of lifetime depression and G allele
carrier status was independent of any reported drug or
alcohol use problems.
Table 1 Demographic, Diagnostic, and rs2075650 Genotypic Information for Participants at Each Experimental Level
Level-1 Level-2 Level-3
Controls Lifetime
depression
Controls Remitted MDD P. remitted and
current
Controls Remitted
MDD
N 571 649 102 97 44 33 25
Age 33.23 (10.06) 34.83 (10.24) 30.06 (10.10) 34.48 (10.69) 39.82 (10.60) 31.42 (9.68) 32.80 (10.21)
Gender
Female 60.2% 77.3% 57% 80% 70.5% 68% 76%
BFI-44
Neuroticism 2.78 (0.77) 3.76 (0.74) – – – – –
Extraversion 3.33 (0.87) 2.96 (0.88) – – – – –
Conscientiousness 3.78 (0.64) 3.56 (0.77) – – – – –
Openness 3.65 (0.58) 3.61 (0.67) – – – – –
Agreeableness 3.86 (0.58) 3.71 (0.66) – – – – –
BSI
BSI-DEP 0.53 (0.62) 1.41 (1.03) 0.26 (0.42) 0.54 (0.59) 2.17 (0.93) 0.27 (0.51) 0.46 (0.57)
– – – – – – –
Drug/alcohol abuse 0.7% 11.7% – – – – –
Financial stability
Very comfortable 10% 7.3% 7.8% 5.2% 4.5% 9.1% 12%
Quite comfortable 55.5% 40.3% 56.9% 60.8% 29.5% 57.6% 56%
Getting by 26.2% 36% 29.4% 29.9% 41% 24.2% 32%
Difficult 7.4% 13.4% 5.9% 4.1% 13.6% 9.1% 0%
Very difficult 0.9% 3% 0% 0% 11.4% 0% 0%
Depression history
0 episodes 100% 0% 100% 0% 0% 100% 0%
1 episode 0% 26% 0% 50% 11% 0% 48%
41 episodes 0% 74% 0% 50% 89% 0% 52%
– – – – – – –
MADRS – – 1.26 (1.80) 3.54 (3.23) 21.86 (7.31) 1.00 (1.54) 2.76 (2.79)
Genotype
AA 76% 67% 74% 74% 57% 70% 72%
GA/GG 24% 33% 26% 26% 43% 30% 28%
HWE p 0.71 0.10 0.69 0.41 0.42 1.00 0.48
Abbreviations: BSI-DEP, Brief Symptom Inventory depression subscale; FFI, Five Factor Inventory; HWE, Hardy-–Weinberg equilibrium; MADRS, Montgomery–A˚sberg
Depression Rating Scale.
Values are given as mean (SD). Note that depression history and drug/alcohol abuse are self-reported measures in Level-1.
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Level-2
Multivariate main effects, diagnosis genotype interac-
tions, and corrections for multiple testing (FDR q-values)
are shown in Table 3. In summary, no significant multi-
variate main effects or diagnosis genotype interactions
were found for the n-back correct moves model or the SoC
initial thinking time model. The SoC subsequent thinking
time model showed no significant multivariate main effects
but did indicate a significant multivariate diagnosis
genotype interaction. Follow-up univariate analysis of the
individual task conditions indicated a significant interac-
tion effect in the 2-move-solution condition (F(2, 202)
¼ 4.515, p¼ 0.012) with the 4-move condition p-value only
marginallyo0.1 (F(2, 202)¼ 2.599, p¼ 0.077). However,
none of the post-hoc contrasts across the interaction term
survived correction.
The SoC average number of moves model also showed a
significant multivariate diagnosis genotype interaction
with the follow-up univariate between-subject tests indicating
significance in the 3-move-solution condition (F(2, 202)¼
5.630, p¼ 0.004) and in the 4-move-solution condition
(F(2, 202)¼ 3.844, p¼ 0.023). Sˇida´k corrected post-hoc pair-
wise comparisons of the interaction term indicated signifi-
cant differences between G allele carriers with current MDD
and all other groups (all pp0.01) for the 3-move solution
condition. This post-hoc univariate interaction result is
shown in Figure 1.
For the emotional word memory task, a significant
multivariate main effect of diagnosis was shown for the
number of correctly recalled immediate words and the
number of correctly recalled delayed words. There was a
significant multivariate diagnosis genotype interaction for
the number of delayed intrusions (not surviving FDR). The
follow-up univariate between-subject tests showed a sig-
nificant interaction for the number of positive intrusions
only (F(2, 225)¼ 6.143, p¼ 0.003). Sˇida´k corrected post-hoc
pairwise contrasts for the interaction term in the positive
word condition indicated that G allele carriers with current
MDD had fewer positive intrusions on delayed recall than
Table 2 Results from the Level-1 Association Between the Big Five Personality Factors and Genetic Models of the TOMM40 Alleles
Main effect of genotype
OR v2 Model tested p uncorrected q FDR corrected
Lifetime depression 1.6 (1.3–2.1) 3.877 ADD 0.0001** 0.0008**
1.7 (1.3–2.3) 4.007 DOM 0.00006** 0.0008**
1.5 (0.6–3.8) 0.876 REC 0.380 0.584
b t p uncorrected q FDR corrected
Current symptoms 0.096 1.589 DOM 0.112 0.287
FFI personality
Extraversion 0.011 0.188 0.851 0.741
Neuroticism 0.078 1.381 0.168 0.321
Conscientiousness 0.002 0.050 DOM 0.960 0.775
Openness  0.023  0.529 0.597 0.705
Agreeableness  0.026  0.616 0.538 0.705
Genotype interaction with current depression score
Extraversion  0.183  3.031 0.002** 0.012*
Neuroticism 0.009 0.164 0.870 0.741
Conscientiousness  0.096  1.932 DOM 0.054 0.164
Openness  0.044  0.922 0.357 0.584
Agreeableness  0.025  0.543 0.588 0.705
Genotype interaction with lifetime depression
Extraversion  0.341  2.963 0.003** 0.012**
Neuroticism 0.143 1.442 0.150 0.321
Conscientiousness  0.034  0.355 DOM 0.723 0.739
Openness  0.040  0.453 0.651 0.713
Agreeableness 0.017 0.196 0.845 0.741
Abbreviations: CI, confidence intervals; FDR, false discovery rate; FFI, Five Factor Inventory; Genetic models, dominant (DOM); additive (ADD), recessive (REC);
OR, odds ratio.
*po0.05; **po0.01.
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AA carriers with current MDD (po0.001), remitted G allele
carriers (p¼ 0.002), and control G carriers (p¼ 0.026). This
post-hoc univariate interaction result is shown in Figure 2.
Level-3
Analysis of covariance for the sad-neutral contrast indicated
a significant ROI-corrected main effect of genotype in the
left PCC (F(1,51)¼ 17.34, p(FWE)¼ 0.045) at  7  46 20
and the left dorsal ACC (dACC; F(1,51)¼ 17.62, p(FWE)
¼ 0.041) at  4 35 20. A corrected follow-up t-contrast
indicated that greater responses were found for the AA
genotype group compared with the G allele group in both
regions (PCC: t(51)¼ 4.20, p(FWE)¼ 0.021; ACC: t(51)
¼ 4.16, p(FWE)¼ 0.023) (Figure 3). No ROI-corrected
clusters were found for the main effect of diagnosis. The
genotype diagnosis interaction also indicated no ROI-
corrected clusters, suggesting that the effects were due to
genotype alone (Figure 4). The cell sizes for the interaction
term were: AA genotypeþ remitted MDD (n¼ 18), AA
genotype controls (n¼ 23), G alleleþ remitted MDD
(n¼ 7), and G allele controls (n¼ 10). Owing to the rarity
of the minor allele, this result is tentative due to the small
numbers in each group. Repeating the analysis using the
happy-neutral contrast and the fear-neutral contrast
revealed no significant ROI-corrected activations for either
contrast and no diagnosis genotype interaction. See
Supplementary Information for details of medicated parti-
cipants and power.
DISCUSSION
Our main finding is an association between the TOMM40
G allele and a history of depression. Using depression-
related intermediate phenotypes, our results indicate that
rs2075650 polymorphism does not increase the risk of
depression via the expected neuroticism pathway but rather
appears to interact with extraversion. This effect was not
Table 3 Multivariate Main Effect and Interaction Results from the Level-2 Neuropsychological Test Battery
Multivariate main effect
(Pillai’s Trace)
F df p-value FDR
q-value
n-back (1-back, 2-back, 3-back)
Number correct D 1.939 6, 440 0.073 0.230
G 0.064 3, 219 0.979 0.968
DG 0.993 6, 440 0.429 0.625
Stockings of Cambridge (2-, 3-, 4-, 5-moves)
Initial thinking time (ITT) D 0.862 8, 400 0.549 0.718
G 1.175 4, 199 0.323 0.513
DG 0.226 8, 400 0.986 0.968
Subsequent thinking time (STT) D 0.692 8, 400 0.699 0.823
G 1.296 4, 199 0.273 0.495
DG 2.623 8, 400 0.008** 0.047*
Average number of moves D 1.397 6, 402 0.215 0.440
G 1.470 3, 200 0.224 0.440
DG 3.270 6, 402 0.004** 0.047*
Emotional word memory (positive, negative, neutral)
Number of correctly recalled immediate words D 4.033 6, 448 0.001** 0.024*
G 2.452 3, 223 0.064 0.230
DG 1.911 6, 448 0.078 0.230
Number of immediate intrusions D 0.387 6, 448 0.887 0.968
G 0.155 3, 223 0.926 0.968
DG 0.962 6, 448 0.451 0.625
Number of correctly recalled delayed words D 3.040 6, 448 0.006** 0.047*
G 1.673 3, 223 0.174 0.403
DG 0.691 6, 448 0.657 0.814
Number of delayed intrusions D 1.159 6, 448 0.327 0.513
G 1.808 3, 223 0.146 0.382
DG 2.510 6, 448 0.021* 0.099
Abbreviations: D, diagnosis; df, degrees of freedom; DG, diagnosis and genotype interaction; FDR, false discovery rate; G, genotype.
*po0.05; **po0.01.
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found globally at the behavioral level but only appeared
within the context of depression, namely the risk allele
carriers displayed decreased extraversion if they had
lifetime or current depression. The TOMM40 risk allele
also appeared to be associated with cognitive deficits during
current depressive episodes, specifically mild executive
dysfunction and a decrease in positive memory intrusions,
and may therefore act by enhancing cognitive deficits
within the most vulnerable group. Our imaging data
identified functional differences between the protective
and risk allele carriers that did not appear to be influenced
by diagnosis. Instead of the predicted increase in activation
in ROIs during sad emotion processing, we found a stable
decrease of activity in the PCC and a state/medication-
dependent deactivation in the dACC.
Decreased Extraversion and Depression
Both extraversion and neuroticism are key personality traits
for affective processing (Canli, 2004). In fact, it has been
claimed that 50% of the genetic vulnerability to depression
is shared with genes that influence the expression of
neuroticism (Juhasz et al, 2009), whereas extraversion is
only weakly linked (Kendler et al, 2006b). Our results
showed no interaction between TOMM40 and depression
on neuroticism but a significant finding for decreased
extraversion. TOMM40 may therefore act as a particular
mediator of the extraversion trait alone, reducing expres-
sion in carriers of the risk allele with either a history of, or
current, depressive episodes. This is compatible with a
number of studies implicating low extraversion as a risk
factor for developing depression (Cox et al, 2004; Farmer
et al, 2002; Jylha and Isometsa, 2006; Jylha et al, 2009)
although the association is not as strong as with neuroti-
cism. It may be that even mildly decreased extraversion is
important during depressive episodes (Jylha et al, 2009)
where it might inhibit recovery. Further study will be
needed to clarify this relationship. In addition, given the
established relationship between TOMM40 and AD, it is
interesting to note that a decrease in extraversion, as well as
increases of neuroticism, have been found to precede and
represent risk factors for AD and thus may be markers of
early dementia onset (Robins Wahlin and Byrne, 2011).
Executive Dysfunction and a Reduced Positive Memory
Bias
Poor performance during the SoC task has been previously
demonstrated in depressed patients (Beats et al, 1996; Elliott
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Stockings of Cambridge (SoC) task detailing the direction of interaction for
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categories. Error bars represent SE. *pp0.05.
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et al, 1996), a finding often interpreted as a top-down,
executive control deficit (Disner et al, 2011). Our finding
of some influence of the TOMM40 risk allele on SoC
performance in currently depressed, but not remitted
depressed, individuals suggests that there may be a state-
dependent effect of the risk allele on executive dysfunction.
Although the effect was modest, and therefore caution
is needed, it is of interest that impaired cognitive function,
in addition to low extraversion, has been associated with
poorer treatment outcome in depression (Clark et al, 2009),
consistent with a potential role for the TOMM40 risk allele
as a marker of worse illness course.
Negative bias is central to cognitive models of depression
where positive bias associated with normal processing of
affective stimuli is reduced (Elliott et al, 2011; Ellwart et al,
2003; Harmer et al, 2009). In our study, the bias towards the
intrusive recall of positive words was seen in all the groups
apart from currently depressed individuals carrying the risk
allele. The risk allele may therefore play a part in the biasing
of the retrieval of affective material from memory
(Hamilton and Gotlib, 2008).
Neuronal Differences in Cingulate Activity
Using fMRI during face emotion processing, an imaging
marker for depression (Scharinger et al, 2010), we found
that possession of the risk allele, independent of a history of
depression, was associated with altered function of the
cingulate cortex during sad emotion processing. Given the
finding was in both remitted depressed participants and
controls, it appears that the risk allele is associated with
a general alteration in affective processing. In depression,
both morphological changes (Caetano et al, 2006) and
dysfunction of the dACC (Fu et al, 2004) have been
demonstrated and implicated as predictors of treatment
response (Fu et al, 2008; Pizzagalli et al, 2001; Pizzagalli,
2011). Dysfunction of the dACC is consistent with theories
of impaired top-down control in depressed individuals
(Disner et al, 2011). The PCC is associated with affective
self-referential processing (Johnson et al, 2009; Vogt et al,
2006), and abnormal responses in this region have been
reported in depressed subjects (Berman et al, 2011; Drevets,
2000). One possible interpretation of our results is that the
presence of a trait alteration in function in the cingulate
cortex, through carrying the risk allele, may interact with
those occurring during depression. In particular, the effect
in the dACC may contribute to impaired recovery from
depression. Of interest also, given the putative link between
depression and AD, is that one of the earliest detectable
hypo-metabolic neuronal regions in AD is the PCC
(Minoshima et al, 1997), with the TOMM40 risk allele
known to impact brain regions vulnerable to AD by
downstream apoptotic processes (Ferencz et al, 2012).
These findings suggest that a potential mechanism for
depression as a precursor to AD may be via dysfunctional
activity within the cingulate.
Limitations
The main limitation of the current study was our focus on a
single SNP. Although significant associations were found, it
is difficult to know how much of an effect this polymorph-
ism has without further understanding the influence of
other mutations within the TOMM40-APOE locus. Although
the Level-1 cohort was a large sample, the nature of
questionnaire data and subsequent response biases means
that further replication will be required to support our
findings, particularly as the diagnosis of depression was
self-reported. In our Level-2 findings, the main effect of
emotional word bias did not survive FDR correction, thus
this result will need replication. In addition, the sample size
for the Level-3 imaging study was modest by genetic
standards and as such replication of this result will be
required. Also, only remitted depressed and healthy
individuals were imaged, and therefore we cannot general-
ize our findings to a currently depressed state.
Summary
The current study presents evidence of a possible new risk
allele for the development of depression. Our results
indicate that possession of the TOMM40 G allele is
associated with lifetime risk of depression and with altered
neural processing of sad faces shown by fMRI. In addition,
current depressive states revealed further genotypic asso-
ciations with impaired cognitive performance, changes in
positively biased affective recall, and a decrease in
extraverted personality traits. Extrapolation of these results
beyond the current study remains speculative given that this
is the first study to investigate the link between depression
and TOMM40 rs2075650. It may be that the risk allele
distorts the development of neural systems processing
executive function and emotion and that therefore the
effects of the TOMM40 G allele might be expected not only
to increase risk of depression but also to prolong illness.
This is currently unknown and would be worthy of further
investigation. It is intriguing to consider that the same
underlying alterations in neural system function may also
contribute to vulnerability for the development of dementia,
potentially explaining the enhanced risk of AD in indivi-
duals who have suffered depression in the past, and the
reduced age of onset for AD in these vulnerable popula-
tions. Further investigations will be needed in order to fully
understand the relationship between TOMM40, dementia,
and depression.
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